Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

ly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

This press release contains forward-looking statements including without limitation statements related to the potential safety, efficacy and commercial potential of voreloxin; planned additional clinical testing and development efforts for voreloxin; and the timing of enrollment in the ongoing clinical trials of voreloxin. Words such as "promising," "effort," "suggest," "appears," "encouraging," designed," "look forward," "estimate," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)...  Genomic Health, Inc. (Nasdaq: GHDX ) ... from a health economic analysis suggesting that use of ... a significant reduction in direct medical costs and improve ... effects of unnecessary treatment.  "By providing ... measures, as demonstrated in this analysis, the Oncotype DX ...
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... DUBLIN, Ireland , September 11, ... ,Research and Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has ... Radio Frequency Identification (RFID) Market in ... Cabinets) - Industry Analysis, Size, Share, ...  report to their offering.  ,     (Logo: ...
Breaking Medicine Technology:Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 2Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 3Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 4Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 5Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3
... 2012 Reportlinker.com announces that a new ... catalogue: Top 200 Biopharmaceuticals ... http://www.reportlinker.com/p0572074/Top-200-Biopharmaceuticals-Industry-Report-Global.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharma The Global Biopharmaceuticals ... This report is an in-depth ...
...  Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced ... preparing to issue a report regarding the Company,s ... statement: The Company believes that its ... requirements and industry standard practices.  Questcor markets H.P. ...
Cached Medicine Technology:Top 200 Biopharmaceuticals Industry Report (Global) 2Top 200 Biopharmaceuticals Industry Report (Global) 3Top 200 Biopharmaceuticals Industry Report (Global) 4Questcor Pharmaceuticals Issues Statement 2
(Date:9/13/2014)... Va. (PRWEB) September 13, 2014 Happiness is ... to healthier living and achieving goals. That's what LWell ... pleased to announce that Stephens, a life coach who has ... was a teenager, will present her "Happiness is a Choice" ... 6:30 p.m. , This event is being offered ...
(Date:9/13/2014)... MD (PRWEB) September 13, 2014 Deaf Awareness ... The Hearing and Speech Agency hosts a week-long ... Sign Language (ASL) as the main form of communication. ... the schedule includes an ASL film night, a yoga class, ... open to the entire community. , The schedule is as ...
(Date:9/13/2014)... (PRWEB) September 13, 2014 Motion Graphics artist ... new transition pack entitled TransPack Volume 2 exclusively for Final ... fun way to transition from one clip to the next.” ... can never have too many transition options and TransPack Volume ... TransPack Volume 2 is a package of 30 thematic transitions ...
(Date:9/13/2014)... September 13, 2014 Although it’s cooled ... into mosquito high season are the state’s southern cities ... areas. With a rise in mosquitoes carrying West ... a partnership with Dixie State University’s Dr. Barnum and ... a product called NutriVex. , NutriVex is in its ...
(Date:9/12/2014)... As low testosterone lawsuit claims continue ... two of the U.S. Food & Drug Administration (FDA) ... to discuss controversial public health issues surrounding testosterone replacement ... and the Drug Safety and Risk Management Advisory Committee ... population for testosterone replacement therapy and the potential risk ...
Breaking Medicine News(10 mins):Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 2Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 3Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 2Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 3Health News:Today a new TransPack Volume 2 transition was announced from Pixel Film Studios for Final Cut Pro X. 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 2Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 4Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 5
... Organisation (WHO) Monday hailed the progress of governments of Western ... region needed greater effort to effectively control the disease. ... of detecting at least 70 percent of TB cases and ... Maaren, regional adviser for the health body's TB programme. ...
... miniature robot that can be inserted through an incision ... body. ,Researchers from Ritsumeikan University and the ... that is controlled remotely once placed inside the body. ... centimeters (0.79 inches) in length and one in diameter. ...
... that some patients who complete bariatric surgery can develop ... deficiency, called Wernicke encephalopathy. , The researchers ... about their conclusions by extensive survey of data relating ... surgery. , The syndrome - Wernicke encephalopathy ...
... inhaled anesthetics increase the number of amyloid plaques in ... of neurodegenerative diseases like Alzheimer's. ,Roderic Eckenhoff, ... Pennsylvania's Department of Anesthesia and Critical Care, and his ... edition of Neurobiology of Aging. ,Every year ...
... hardly 29 per cent of the asthmatic children surveyed had ... as a dangerous trend for not vaccinating their kids against ... officials have warned. ,Actually it has been warned ... fall victims to pneumonia or acute respiratory disease. Inactivated flu ...
... possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). The ... and Technology and the Environmental Protection Agency of the ... clear how dangerous these PBDEs are, though some types ... is strikingly similar to that of PCBs, which are ...
Cached Medicine News:Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: